Bright Minds Biosciences (DRUG) Intangibles (2020 - 2022)
For the quarter ending Q3 2021, Intangibles changed N/A year-over-year to $1588.8, compared with a TTM value of $1588.8 through Sep 2021, changed N/A, and an annual FY2021 reading of $1588.8, up 6.78% over the prior year.
Bright Minds Biosciences (DRUG) has disclosed Intangibles for 1 consecutive years, with $1588.8 as the latest value for Q3 2021.
- Intangibles reached $1588.8 in Q3 2021 per DRUG's latest filing.
- Across five years, Intangibles topped out at $1588.8 in Q3 2021 and bottomed at $1588.8 in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 4.41 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 11,640.44 |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 418.50 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.29 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Bright Minds Biosciences | 464.72 Mn | 405.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 1,568.68 |
| Mar 31, 2022 | 1,578.95 |
| Dec 31, 2021 | 1,586.67 |
| Sep 30, 2021 | 1,588.82 |
| Sep 30, 2020 | 1,500.85 |